Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎, New York, NY 10065
(646) 856-9261
[email protected]

First-in-class oncology drug development

Inspirna (formerly Rgenix) is a clinical-stage biopharmaceutical company developing first-in-class/best-in-class drug candidates that target critical cancer drivers.

RNA-DRIVEr™ Discovery platform

Our discovery platform leverages RNA biology to discover novel RNA dysregulated cancer drivers that can be targeted by small molecules and biologics.

Deep clinical and preclinical pipeline

Clinical programs are first-in-class oral small molecules in development for patients with RAS mutant CRC (ompenaclid (RGX-202); Phase 1b) as well as SCLC and NSCLC (RGX-104; Phase 1b/2).


Ompenaclid (RGX-202)

Ompenaclid (RGX-202) is an oral small molecule inhibitor of SLC6A8 that induces apoptosis (cell death) of colorectal cancer cells.


Abequolixron (RGX-104)

RGX-104 is an oral small molecule activator of LXR/APOE that inhibits the growth of tumor blood vessels (angiogenesis) and activates tumor myeloid cells to enhance the immune response against tumors.



RGX-019 is a monoclonal antibody-drug conjugate (ADC) that targets MERTK to selectivity kill cancer cells and activate tumor myeloid cells.


Clinical Trials

We are actively recruiting patients for clinical trials of ompenaclid (RGX-202) and RGX-104.


Our Science

Science underlying Inspirna’s technology and pipeline has been published in leading scientific journals